# L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

> **NCT00125788** · PHASE2 · COMPLETED · sponsor: **Emmaus Medical, Inc.** · enrollment: 70 (actual)

## Conditions studied

- Sickle Cell Anemia
- Thalassemia

## Interventions

- **DRUG:** L-glutamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00125788
- **Lead sponsor:** Emmaus Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2021-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125788, "L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00125788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*